Abstract Peter J Psaltis¹, Stan Gronthos², Stephen G Worthley¹ and Andrew CW Zannettino²

¹Cardiovascular Research Centre, Royal Adelaide Hospital; Department of Medicine, University of Adelaide, South Australia, 5000. ²Division of Haematology, Institute of Medical and Veterinary Science; Department of Medicine, University of Adelaide, South Australia, 5000.

Abstract

Coronary artery disease (CAD) and congestive heart failure (CHF) are leading causes of morbidity and mortality in Western communities and represent a growing economic burden to most health systems. Cell-based therapy represents a novel treatment strategy to treat CAD and CHF. The first part of this two-part review will address the biological properties and functional potential of different cell types that have been trialled in preclinical cardiovascular research. Part two will focus on the clinical application of these cells and will discuss the lessons learnt from clinical trial experience so far.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN